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INTRODUCTION 
It may fairly be claimed that up to the last decade 
no antiepileptic drug (AED) had undergone 
rigorous testing. Coatsworth I in a comprehensive 
review of AED assessment reported three con- 
trolled trials up to 1971, and Richens (1976) was 
able to identify some 17. Gram and coworkers 
found 51 by 1982, but the majority suffered gross 
methodological deficiencies. In the past decade 
the situation has changed dramatically, the 
number of controlled AED trials currently in 
progress must exceed the total of those completed 
before 1983. The development programmes of 
the new AEDs registered in recent years have 
necessarily been innovative, and methods of 
AED testing are still undergoing rapid evolution- 
ary change. Conventional phase II AED trials are 
usually placebo controlled studies employing 
designs of either single period parallel groups or 
multiple periods within patients. Since it is, in 
general, unacceptable to withhold effective treat- 
ment from a patient with epilepsy, during 
conventional AED trials the experimental drug is 
added to the presumably partially effective 
medication already being taken (add-on trials). 
Although widely regarded as an ethical necessity, 
this approach poses a number of problems which 
often makes this design difficult to interpret: (1) 
Drug interactions may confound both therapeutic 
and adverse ffects. Elevation of blood levels of 
comedication may cause intoxication, which may 
be wrongly attributed to the experimental gent 4"5 
and efficacy can be wrongly ascribed to a new 
product because it causes an increase in con- 
centrations of comedication 6. Conversely in- 
creased clearance of the comedication may 
reduce apparent efficacy. (2) Induction of meta- 
bolism by the comedication may produce lower 
than expected blood levels and result in a failure 
to demonstrate any effect of the experimental 
drug. (3) Efficacy and adverse vents may depend 
on a pharmacodynamic synergy with the 
comedication. 
A number of alternative trial designs are now 
available and increasing attention has recently 
been directed to ethically acceptable monothe- 
rapy designs 7. One approach, first adopted by 
Bourgois et al 8, in the development of Felbamate, 
is the performance of monotherapy trials in 
patients whose AEDs had been withdrawn to 
facilitate capture of seizures by telemetry, as part 
of a preoperative assessment protocol. The 
conduct of such trials is difficult and complex. The 
patients are in an unstable state and there may be 
only a brief interval between capturing sufficient 
seizures to meet the needs of preoperative 
assessment and the onset of serial seizures 
demanding immediate control. To be of demons- 
trable efficacy under these circumstances, the test 
drug must act swiftly. If the onset of drug action is 
delayed by one or two days, the opportunity to 
prove an effect may be missed. This may happen 
if the half life is long or efficacy depends on an 
active metabolite or if there are constraints on the 
rate of dose escalation. In many patients, it is 
impossible to achieve monotherapy if seizure 
frequency increases rapidly before existing medi- 
cation is fully withdrawn 8. 
We report two variants of this design: an open 
trial of remacemide hydrochloride (Fisons CR 
2083), and a controlled trial of tiagabine (Abbott 
M90-511 TIA-102) in which the test treatment 
was introduced prior to withdrawal of other 
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medication. This last approach may avoid many 
of the difficulties described above, but will 
prolong the period of telemetry in patients who 
respond to the active treatment. For reasons 
which will be apparent, both were inconclusive 
but they are reported here as illustrating some of 
the methodological possibilities and problems of 
this novel type of trial design. 
REMACEMIDE HYDROCHLORIDE TRIAL 
The drug 
When administered orally in rodents, re- 
macemide hydrochloride protects against maxi- 
mal electroshock induced seizures with a potency 
similar to that of phenytoin, phenobarbitone or 
carbamazepine and greater than valproate. It is 
also effective against absence-like seizures in 
rats 9. The desglycinyl derivative of remacemide is 
an active metabolite in the rat and has also been 
identified in the dog and man m'~l. In healthy 
volunteers the drug has been generally well 
tolerated at single doses of up to 400mg or at 
150 mg q.i.d, for six days. Minor adverse events 
(gastrointestinal upset, nausea and lightheaded- 
ness) were observed at higher doses. The 
mechanism of action of remacemide hydroch- 
Ioride has not been fully elucidated but it appears 
to differ from that of other AEDs. The compound 
has been shown to enhance the survival of mice in 
a hypoxic environment and to exert a neurop- 
rotective effect against global and focal cerebral 
ischaemia in rodents and higher species 12. 
Patients 
Ten male patients aged between 19-41 years 
(average, 25.7) entered the study. Table 1 
summarizes the demographic and pretreatment 
Table 1: Patient characteristics and seizure history of patients taking part in the 
remacemide trial 
Mean value 
or frequency 
Number of patients: 
Age (years): 
Sex: 
Duration of epilepsy (years): 
Etiology: 
Number of seizures per month: 
Types of seizures experienced: 
Number of seizure types: 
Standard Anticonvulsants: 
10 
Mean 25.7 
Range 19-41 
Males l0 
Females 0 
Mean 19.4 
Range I 1-35 
Febrile convulsions 2 
Birth injury I 
History of head injury l 
History of haemorrhage l 
Idiopathic 1 
Unknown 4 
Mean 22.4 
Range 4-84 
Simple partial 6 
Complex Partial 9 
Complex partial 
with secondary 
generalisation 6 
Generalised tonic 
clonic 1 
Three types 3 
Two types 5 
One type 2 
Carbamazepine 6 
Vigabatrin 5 
Sodium valproate 4 
CIobazam 4 
Phenytoin 2 
Primidone 2 
Clonazepam 2 
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characteristics of the patients. Patients were 
capable of giving informed consent in writing, and 
had confident diagnosis of epilepsy supported by 
a previous EEG workup. Exclusion criteria were 
the existence of any significant medical history or 
laboratory abnormalities other than those at- 
tributable to the concomitant AEDs: alcohol 
consumption greater than 21 units per week: 
history of chronic drug abuse, heavy smoking 
(more than 15 cigarettes a day); chronic use of 
non-steroidal anti-inflamatory drugs or antihis- 
tamines; history of poor compliance and/or 
pseudoseizures. 
Throughout this phase patients were resi- 
dent in the telemetry monitoring facility of the 
Maudsley Hospital, under continuous nursing 
supervision and video monitoring. The duration 
of Phase A was five days, or until 12 hours 
following discontinuation of the drug--whichever 
was shorter. At the end of Phase A, patients 
were assessed for their eligibility to enter 
Phase B. 
Phase B 
Study  des ign  
After a pre-study screening and seizure docum- 
entation over at least four weeks, the withdrawal 
of AEDs and presurgical EEG telemetry, eligible 
patients received remacemide hydrochloride 
150mg q.i.d, for a maximum of 28 days. The 
study treatment was administered initially as 
monotherapy but in some patients continuing 
seizures required the reinstitution of their stan- 
dard antiepileptic drugs. The study was carried 
out in two phases: Phase A (first five days) and 
Phase B (6 to 28 days). 
Phase A 
Patients satisfying the study entry criteria re- 
ceived remacemide hydrochloride, as above. 
Phase B was the continuation of the studv 
from the end of Dav 5 (i.e. Phase A) to dav 28. 
Only patients completing all 5 days of Phase A 
were to be considered for Phase B. During 
Phase B patients were discharged home but 
were to be evaluated on at least four occasions. 
The patient kept a daily record of seizure 
frequency and type, adverse events, and con- 
comitant medications throughout this phase. 
During Phase B, patients would be on re- 
macemide hydrochloride monotherapy, or on 
remacemide hydrochloride plus standard AED 
comedication, or on remacemide hvdrochloride 
monotherapy at day 6, followed by addition 
of standard AED at any point during Phase 
B. Remacemide hydrochloride was reduced 
gradually over four days at the end of phase 
B in order to reduce the risk of withdrawal 
seizures. 
Table 2: Total seizure frequency during Phase A of the remacem~de trial 
Patient Baseline Phase A 
number (Day -1) 
Day 1 Day 2 Day 3 Day 4 Day 5 
1 7 4.6* . . . .  
2 2 6 7.7* -- -- -- 
3 7 7.2* . . . .  
4 3 I 3 2 0 19.2" 
5 I 0 0 I I I 
6 11 2 1 Manv Many -- 
7 7 3 I 1 ~ '* _.t~ 
8 1 2 I 2 1.5" -- 
9 . . . . . .  
It) II 2 I - - - 
Comparison of  Baseline vs Day I: P = 0.138 
Comparison of  Baseline vs Day 2: P = 0.198 
* Estimated by l inear interpolation from incomplete 24 hour periods of  at least 12 hrs. 
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Number of patients experiencing event 
Baseline Phase A Phase B Follow-up 
Musculo-skeletal: Myalgia 
Nervous ystem: Dizziness 
Headache 
Hyperaesthesia 
Hypoaesthesia 
Paraesthesia 
Vision: Vision abnormal 
Psychiatric: Anxiety 
Confusion 
Somnolence 
Thinking abnormal 
Digestive system: Vomiting 
Nausea 
Respiratory system: Bronchitis 
Hyperventilation 
General symptoms: Fatigue 
Fever 
Influenza-like symptoms 
Malaise 
Pain 
Other medical events: 
Total number of patients 
Number of patients experiencing events in each period 
0 
0 
2 
0 
0 
0 
0 
0 
0 
0 
I 
(I 
0 
0 
0 
I 
1 
1 
1 
0 
2 
I0 
6 
I 
I 
0 
1 
0 
0 
0 
2 
0 
1 
10 
7 
0 0 
0 0 
0 1 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
1 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 1 
0 0 
1 l0 
I I 
Results 
Efficacy 
Seizure frequency was recorded at baseline and 
throughout the study period up to and including 
day 5 (Table 2). Additional data after this time 
were available only for patient 5, who completed 
Phase B of the study. Seizure frequency for this 
patient did not appear to alter significantly during 
this phase. Total seizure frequency on days 1 and 
2 ~vere compared with baseline (day -1) using a 
Wilcoxon Matched Pairs Signed Rank test. 
Statistical analysis of data on days 3, 4 and 5 was 
not possible due to insufficient sample size 
(caused by patient withdrawals). A total of nine 
patients were included in an analysis of total 
seizure frequency, which compared ay 1 of the 
study with baseline (day -1)  and a total of seven 
patients were included in an analysis of total 
seizure frequency which compared ay 2 of the 
study with baseline (day -1). Although a 
reduction of median seizure frequency was seen 
on days 1 and 2 when compared with baseline, 
this difference did not achieve statistical sig- 
nificance. Analysis of complex partial seizure 
frequency and secondarily generalized seizure 
frequency also showed no statistically significant 
differences between the two study days and 
baseline. It was not possible to analyse simple 
partial and generalized seizure frequencies due to 
insufficient data. 
Safety 
Of the 10 patients who received remacemide 
hydrochloride, only one patient received the drug 
for the complete study period of 28 days. The 
remainder stopped study treatment between one 
and five days after the start of dosing, due to 
adverse vents or deterioration of epilepsy (Table 
3). Nine patients experienced adverse events 
during the study. Six patients experienced events 
during the baseline period, seven during Phase A 
of the treatment period, one patient during Phase 
B and one patient during the follow-up period. 
The most commonly experienced event during 
the treatment period was headache (three pati- 
ents). No serious events were reported uring the 
study. Seven patients experienced events which 
were thought to be possibly related to test 
treatment and included myalgia, malaise and 
dizziness, hyperaesthesia, vomiting, confusion, 
hypoaesthesia, nausea, anxiety, paraesthesia and 
hyperventilation, and abnormal vision. 
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TIAGABINE TRIAL 
The drug 
Tiagabine hydrochloride (HCI) is a potent and 
specific inhibitor of GABA uptake by glial and 
neuronal elements in vitro. Following administra- 
tion by intraperitoneal injection it has potent 
anticonvulsant activity in animal models. In 
volunteers, adverse events can be observed at 
doses above 12 mg/day, including dizziness, 
headache, somnolence, abnormal vision, poor 
concentration, incoordination, stupor, confusion 
or  nausea  13. 
human chorionic gonadotrophin pregnacy test at 
day -1.  Patients taking primidone or phenobar- 
bital had this medication discontinued prior to 
admission to the study. The plasma phenobarbital 
concentration was required to be -< 10/zg/ml 
prior to day -1. 
Exclusion criteria included: history of relevant 
psychiatric illness, progressive CNS disease, other 
medical disease, non-compliance with medication 
or medical advice, recent history of alcoholism, 
drug abuse or addiction, consumption of 30 or 
more units of alcohol per week, significant 
laboratory abnormalities other than those at- 
tributable to antiepileptic drugs. 
Patients 
Eleven patients entered the study with ages 
between 17 and 52 (mean, 32.8) years. The mean 
age for the patients in the tiagabine HCL and in 
the placebo group was 38.3 and 23.3 years, 
respectively. Patient characteristics are shown in 
Table 4. Patients were capable of signing an 
informed consent, were hospitalized uring the 
double-blind and washout phases, and had a 
diagnosis of epilepsy with complex partial se- 
izures supported by observed ictal events docu- 
mented by reliable witnesses and confirmed by at 
least one of the following: (1) ictal electroen- 
cephalogram (EEG), (2) interictal EEG demons- 
trating epileptiform activity, (3) computed tom- 
ography or magnetic resonance imaging showing 
a focal cerebral esion consistent with complex 
partial seizures. Additional requirements in fe- 
male patients were at least one of the following: 
(1) being surgically sterilized, (2) at least one 
year postmenopausal, (3) an intrauterine device 
in place for at least one month, (4) use of an oral 
contraceptive for at least one menstrual cycle, 
and for the duration of the study; (5) a negative 
Study design 
The study consisted of an open phase (28 days), a 
double-blind treatment phase (seven days) and a 
washout phase (24 hours). During the screening 
visit of the open phase, patients provided written 
informed consent and a medical history, under- 
went a physical examination and laboratory tests. 
Within four weeks following the Screening Visit, 
eligible patients were admitted to the hospital, 
where they remained for the duration of the 
study. On day -1  of the open phase (the day 
before starting the double-blind treatment 
phase), an interval medical and seizure history, 
and laboratory tests were obtained. During the 
seven-day double-blind phase, randomized pati- 
ents were dosed every four hours with the 
tiagabine HCI or matching placebo. Assignment 
to the treatment group was balanced (1:1) 
between placebo and tiagabine HC1. Patients had 
their dose of study treatment titrated by a 
physician blinded to medication to achieve either 
the maximum well tolerated ose or 66 mg/day 
(or equivalent number of placebo capsules). 
Concomitant AEDs were discontinued with start 
Table 4: Patient characteristics of the patients who took part in the tiagabine trial 
Tiagabine Placebo Total 
Characteristic N = 7 N = 4 N = 11 
Age (years): mean (sd) 38.3 (9.96) 23.3 (6.13) 32.8 (11.3) 
range 24-52 17-31 17-52 
Sex: males 5 3 8 
females 2 1 3 
Race: Black 0 1 0 
Caucasian 7 3 10 
Weight (Kg): mean (sd) 75.4 (15.5) 74.8 (14.9) 75.2 (14.5) 
range 50-96 63-95 50-96 
Height (cm): mean (sd) 173.1 (9.92) 179.8 (10.6) 175.5 (10.2) 
range 157-184 167-189 157-189 
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of study medication. Tiagabine HCi (or placebo) 
was then administrated in six daily doses and 
titrated with gradually increasing doses, starting 
with 2 mg/dose and increasing 1 mg/dose every 
three to five doses. For the next eight days, 
patients' interval seizure histories, adverse ev- 
ents, AED and study drug plasma concentrations, 
and laboratory values were assessed periodically. 
On day 8 study medication was stopped. Follow- 
ing a 24-hour washout phase (day 9) patients 
received a final evaluation, their original AEDs 
were reinstituted, and patients were discharged 
from the study. Escape criteria to stop drug 
administration during the double-blind phase 
were established a priori and included: convulsive 
status epilepticus, three convulsive seizures 
within any 24 hours or two convulsive seizures 
within any three hours. In addition, escape 
criteria depending on each patient's baseline rate 
(number of seizures in the open phase divided by 
28) were established. 
Baseline rate -<0.25: drug administration was 
stopped if the patient had more than four 
seizures/day or five seizures/48 hours. 
Baseline rate >0.25 and <--0.50: drug administra- 
tion was terminated if the patient had more than 
five seizures/day or more than seven seizures/48 
hours. 
Baseline rate >0.50 and <-I.00: drug administra- 
tion was terminated if the patient had more than 
six seizures/day or more than eight seizures/48 
hours. 
Baseline rate >1.00: drug administration was 
terminated if the patient had six or more times 
the baseline rate seizures/day or four or more 
times the baseline rate seizures/48 hours. 
Eligible patients had the option of entering an 
open-label tiagabine HCL extension study (Ab- 
bott M91-595 TIA-104). 
Results 
Eleven patients were enrolled, seven received 
tiagabine HCI and four received placebo. Three 
patients completed the study. 
Premature discontinuation 
Eight patients were prematurely discontinued 
from the study. Five patients were discontinued 
because the number of seizures exceeded the 
escape criteria. Two patients (one on Tiagabine 
and one on placebo) experienced three convul- 
sive seizures within 24 hours. Two patients (on 
placebo) experienced two convulsive seizures 
within three hours. One patient (on Tiagabine) 
experienced more than seven seizures in a 48 
hour period with a baseline rate of 0.32 
seizures/day. One patient (on placebo) was 
discontinued because of protocol violation (not 
keeping a seizure diary during the open phase). 
Two patients (on Tiagabine) were discontinued 
because of an adverse vent. 
Drug administration 
Tiagabine or placebo were administered ap- 
proximately every four hours on the dosing days. 
Of the patients on tiagabine HCI, only two were 
administered the maximum study drug dose of 66 
mg/day, both of whom successfully completed the 
study. Four other patients received maximum 
study drug doses of 42 mg/day, 41 mg/day, 28 
mg/day and 25 mg/day. All patients topped all 
marketed antiepilepsy drugs (AEDs) on or prior 
to day 1 except for one patient who took 
vigabatrin thoughout the study. 
Efficacy 
While the sample size was too small for statistical 
significance to be attained, the results suggest 
efficacy of tiagabine HCi for complex partial, 
simple partial, combined partial and secondarily 
generalized tonic-clonic seizures because the 
patients in the tiagabine HCI group experienced 
fewer seizures than the placebo group in the 
double-blind period. Based on median seizure 
rates, there was no seizure type in either group 
that lessened in frequency during the double- 
blind period but the tiagabine HCI group had less 
increase in seizures of all types (Table 5). 
Complex partial seizures. During the open phase, 
tiagabine HCI-treated patients experienced 0.178 
more seizures per 24 hours than placebo-treated 
patients based on median seizure rates. During 
the double-blind phase, tiagabine HCl-treated 
patients experienced a median of 0.571 fewer 
seizures per 24 hours than placebo-treated 
patients. Both groups, however, did have an 
increase in seizures over baseline. 
Simple partial seizures. During the open phase, 
tiagabine HCl-treated patients experienced 0.054 
fewer seizures per 24 hours than placebo-treated 
patients. During the double-blind phase, tiaga- 
bine HCl-treated patients experienced median 
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Seizure rate per 24h Tiagabine 
N Mean sd 
Placebo 
Median N Mean sd Median 
Complex partial: 
Baseline 7 0.368 0.163 
Double blind phase 7 1.088 0.723 
Simple partial: 
Baseline 5 0.229 0.258 
Double blind phase 5 0.635 0.949 
Combined partial: 
Baseline 7 0.389 0.154 
Double blind phase 7 1.357 0.908 
Secondarily generalized tonic-clonic: 
Baseline 4 0.152 0.074 
Double blind phase 4 0.911 0.958 
0.321 4 0.170 0.135 0.143 
1.154 4 1.771 0.357 1.725 
0.071 2 0.125 0.126 0.125 
0.286 2 2.657 0.486 2.657 
0.321 4 0.188 0.150 0.161 
1.254 4 2.103 0.711 2.014 
0.161 4 0.018 0.021 0.018 
0.711 4 1.699 0.394 1.580 
2.371 fewer seizures per 24 hours than placebo 
treated patients. 
Combined partial seizures. During the open 
phase, tiagabine HCl-treated patients ex- 
perienced 0.160 more seizures per 24 hours than 
placebo-treated patients. During the double-blind 
phase, tiagabine HCl-treated patients ex- 
perienced median 0.760 fewer partial seizures per 
24 hours than placebo treated patients. 
Secondarily generalised tonic-clonic seizures. 
During the open phase, tiagabine HCl-treated 
patients experienced 0.143 more seizures per 24 
hours than patients on placebo. During the 
double-blind phase, tiagabine HCl-treated pati- 
ents had a median of 0.869 fewer seizures per 24 
hours than patients on placebo. 
Table 6: Summary of adverse events reported during the 
tiagabine trial 
Number of patients experiencing 
the event 
Tiagabine Placebo Total 
n = 7 n = 4 n = 11 
Any adverse event 7 
Digestive system: 
Mouth ulceration 1 
Nausea 1 
Nervous system: 
Depression 1 
Diplopia 1 
Dizziness 1 
Headache I 
Insomnia 0 
Paraesthesia 2 
'Feeling outside 
this world' 
2 
0 
0 
0 1 
0 1 
1 2 
2 3 
1 1 
1 3 
l 0 l 
Safety 
Nine patients (82%) experienced at least one 
treatment-emergent adverse event. The most 
frequent adverse events were related to the 
nervous ystem (Table 6). At least one treatment- 
emergent adverse event was reported by 7/7 
(100%) patients receiving tiagabine HCl and by 
2/4 (50%) patients receiving placebo. All adverse 
events were considered to be mild to moderate in 
severity. Ten patients reported headache and 
nine patients reported cheek pain on day -1. 
These were attributed to the insertion of foramen 
ovale electrodes. Two of the 11 patients (18%) 
were prematurely discontinued during the study 
because of adverse events. Both patients had 
been on tiagabine HC1. One patient was discon- 
tinued because of moderate nausea on day 3 and 
another patient was discontinued because of 
moderate depression on day 5 and withdrawn 
consent. 
DISCUSSION 
Conventional double-blind add-on trials can 
be expected to show little difference between 
placebo and novel drugs unless the latter 
are significantly more effective than the exis- 
ting standard treatment j4. While a difference 
greater than 50% is regarded as indicative of 
effectiveness in most add-on trials, this outcome 
is unlikely even if the tested drug is known to 
be effective, as shown by Schmidt 15 who found 
an improvement in only 15% of patients when 
a second marketed rug was added to the regime. 
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Monotherapy trials during presurgical ssessment 
are potentially a good alternative to complement 
add-on studies both to establish efficacy and to 
justify early initiation of more conventional 
monotherapy trials. Pharmacological interactions 
are avoided and since no other therapeutic agents 
are simultaneously present, there is not a basal 
seizure control over which the new agent has to 
demonstrate further efficacy. This implies that 
agents which are at least as active and effective in 
the same patients as already marketed rugs can 
in principle show an effect. 
There are however anumber of problems, both 
theoretical and practical, that complicate the 
interpretation a d conduct of monotherapy trials 
during preoperative assessment. 
Sudden withdrawal of antiepileptic medication 
can be associated with an increase in the 
incidence of seizures ~6 and it is in general not 
clear the extent to which this might be due to 
halting effective therapy or to rebound with- 
drawal effects. The influence of withdrawal 
seizures on results can be minimized by using 
parallel placebo controlled esigns. Although the 
absolute incidence of seizures on the test drug can 
exceed baseline values after withdrawal of stan- 
dard antiepileptic medication, even if the novel 
drug is effective, such increment would be 
expected to be higher in patients on placebo. 
Indeed we found that seizure frequency increased 
during tiagabine treatment after withdrawal of 
standard antiepileptic medication but the incre- 
ment was higher in patients on placebo for all 
seizure types, which suggests that tiagabine 
possesses a degree of effectiveness although the 
small number precluded formal statistical analy- 
sis. No such conclusion would have been possible 
if tiagabine had been tested on an open-label 
basis, as in the case of remacemide hydrochloride. 
Consequently., no comparisons can be drawn 
between the relative efficacy of tiagabine and 
remacemide hydrochloride since the study de- 
signs were disimilar. Whether suppression of 
withdrawal seizures is predictive of efficacy in 
epilepsy may be disputed. An alternative ap- 
proach which avoids this last problem would be to 
randomize patients and start experimental treat- 
ment whilst gradually tapering off standard 
antiepileptic medication during several days 
before surgical assessment. Phenobarbitone, 
whether adminstered as such or arising as a 
metabolite of primidone, has a long half life 
(24-48 hours) and primidone administration was 
consequently stopped between 48 and 72 hours 
before day 1. 
Monotherapy trials during presurgical assess- 
ment allow only a short time available to show 
therapeutic effects. This is an important limitation 
since absolute seizure frequency can increase 
during the trial even if the novel drug is effective 
and in this situation it is difficult for the blinded 
physician to justify continuing the trial. Objective 
escape criteria must be applied to ensure with- 
drawal of patients at risk of harm from continuing 
in the trial (see Material and Methods of 
Tiagabine trial). These criteria should be prag- 
matic and take account of the hazards associated 
with different types of seizure and of the patients' 
habitual seizure type and severity. 
As with add-on trials, presurgical monotherapy 
trials will include patients with particularly 
refractory epilepsy. If a drug does not show 
efficacy in presurgical patients it could still be 
effective in other milder epilepsy. Both tiagabine 
HCI and remacemide HC1 have proven efficiency 
in traditional design trials ~°'~7"18. 
Experiencing a greater than usual seizure 
frequency over a short period of time is 
necessarily disagreeable. Moreover, in many 
centres invasive procedures are often used during 
presurgical assessment. These factors combine to 
give rise to adverse vents which can be difficult 
to distinguish from those induced by the novel 
drug. For instance most of our patients had 
undergone implantation of foramen ovale electr- 
odes under general anaesthesia which is often 
associated with headache, nausea nd facial pain 
lasting for several days, and often overlapped 
with trial day 1. Headache isoften of several days 
duration and was thus indistinguishable from 
headaches possibly induced by the experimental 
drug. Some other adverse vents are more likely 
to be drug specific (drowsiness, tremor, ataxia) 
and can be appropriately monitored to study drug 
safety during monotherapy trials. The pressure of 
time creates the need to escalate the dose of the 
experimental dose faster than would be normal 
practice; this may lead to an incidence of 
drug-induced adverse experiences greater than 
would be encountered with routine use. This 
problem would be alleviated by introducing the 
study treatments more gradually prior to with- 
drawal of comedication. 
Sample size in monotherapy trials during 
surgical assessment will in general be smaller than 
in more conventional trials. This means that 
seizure reduction would have to be greater in 
order to achieve statistical significance. For 
instance, in order to obtain an 80% chance of 
finding existing differences at a 5% significance 
level, seizure reduction will have to be 0.78 times 
the standard eviation for a 10 patient sample, 
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whereas it would have to be 0.25 for 100 patients 
and 0.18 for 200 patients. 
In summary, monotherapy trials during presur- 
gical assessment offer a relatively new methodol- 
ogy to study efficacy and safety of antiepileptic 
drugs during Phase II with minimal interactions 
with standard anticonvulsants. Placebo controlled 
parallel double blind designs are preferable 
because absolute seizure frequency can increase 
during the trial due to withdrawal seizures, even if 
the novel drug is effective. A number of 
difficulties outlined above could largely be over- 
come by gradually introducing and possibly 
titrating to the tolerated limits the experimental 
treatments prior to withdrawal of comedication 
and tapering off standard antiepileptic medication 
over several days before surgical assessment. 
With an effective treatment, patients randomized 
to the active compound at therapeutic doses 
should show no, or less, withdrawal seizures. 
Anticonvulsant pharmacokinetics hould be care- 
fully considered and the timing of withdrawal of 
standard anticonvulsants planned so that sub- 
therapeutic levels are not reached before surgical 
assessment in patients on placebo. If the novel 
drug is effective, admission time and duration of 
invasive recordings would be lengthened but this 
would be amply justified if some patients were 
controlled on the experimental agent and there- 
fore avoided surgery. 
REFERENCES 
1. Coatsworth, J.J. Studies on the Clinical E~cacy of 
Marketed Antiepileptic Drugs. NINDS Monograph No 12. 
Washington, U.S. Government Printing Office, 1971. 
2. Richens, A. Drug Treatntent of Epilepsy. London, 
Kimpson, 1976. 
3. Gram, L., Bentsen, K.D., Parnas, J. and Flachs, H. 
Controlled trials in epilepsy: a review. Epilepsia 1982: 23: 
491-519. 
4. Patsalos, P.N., Shorvon, S.D., Elyas, A.A. and Smith, G. 
The interaction of denzimol (a new anticonvulsant) with 
carbamazepine and phcnytoin. Journal of Neurology. 
Nearosurgerv and Psychiatry 1985: 48: 374-377. 
5. Treiman, D.M. and Ben-Menachem, E. Inhibition of 
carbamazepine and phenytion metabolism by nafimidone, 
a new antiepileptic drug. Epilepsia 1987: 28: 699-705. 
6. Hansen, J.M., Kristensen, M. and Skovsted, L. Sulthiame 
(Ospolot) as inhibitor of diphenylhydantoin metabolism. 
Epilepsia 1968: 9: 17-22. 
7. Pledger, G.W. and Kramcr, L.D. Clinical trials of 
investigational ntiepileptic drugs: monotherapy designs. 
Epilepsia 1991: 32: 716-721. 
8. Bourgeois, B., Leppik, I., Sackellares, J.C. el al. 
Felbamate: a double-blind controlled trial in patients 
undergoing presurgical evaluation of partial seizures. 
Neurology 1993: 43: 693-696. 
9. van Luijtelaar, E.L.J.M. and Coenen, A.M.L. Effects of 
remacemide and its metabolite FPL 12495 on spike-wave 
discharges, electroencephalogram nd behaviour in rats 
with absence epilepsy. Neuropharmacology 1995: (in 
press). 
10. Palmer, G.C., Clark, B. and Hutchinson, J.B. Antiepilep- 
tic and neuroprotective potential of remacemidc hydroch- 
Ioride. Drugs of the Future 1993: 18: 1021-1042. 
I1. Palmer. G.C., Murray, R.J., Wilson, -T.C.M., et al. 
Biological profile of the mctabolites and potential 
mctabolites of the anticonvulsant remacemide. Epilepsy 
Research 1992: 12: 9-21). 
12. Bannan, P.E., Graham, D.I., Lees, K.R. and McCulloch, 
J. Neuroprotectivc effect of rcmacemide hydrochloride in
focal cerebral ischemia in the cat. Brain Research 1994: 
664: 271-275. 
13. Pierce, M.W., Suydak, P.D., Juvstavson, L., Mengel, 
H.B., McKelvy, J.F. and Maut, T. Tiagabine. In: The New 
Antiepileptic Drugs. (Eds E. Perucca, F. Pisant. A. 
Richens.) Epilepsy Research 1991: (Suppl. 3): 157-160. 
14. Temkin, N.R. and Wilensky, A.J. New AEDs: are the 
compounds or the studies incffective? Epilepsia 1986: 27: 
644-645. 
15. Schmidt, D. Two antiepilcptic drugs lor intractable 
epilepsy with complex partial seizures. Journal of 
Neurology. Neurosurgery and Psychiatry 1982: 45:1119- 
1124. 
16. Marks, D.A., Katz, A., Scheyer, R. and Spencer, S.S. 
Clinical and electroencephalographic effects of acute 
anticonvulsant withdrawal in epileptic patients. Neurology 
1991: 41: 508-512. 
17. Brodie, M., Lassen, L. Ch. et al. Randomized, Double- 
blind, placebo-controlled, parallel-group study of safety 
and efficacy of tiagabine administered three times daily as 
adjunctive treatment for partial seizures. Epilepsia 1994: 
35(Suppl. 7): 61. 
18. Duncan, J., Sander, J.W., Lyby, K. et al. Long-term safety 
and efficacy evaluation of patients with partial seizures 
treated with tiagabine in two open extension studies. 
Epilepsia 1994: 35(Suppl. 7): 74. 
